Randomized controlled trial - Design and Randomization

Classifications and Methods of Randomized Controlled Trials Introduction Randomized controlled trials (RCTs) are the gold standard for evaluating whether an intervention causes an effect. The fundamental principle is simple: by randomly assigning participants to either receive a treatment or a control, researchers can compare outcomes and determine whether differences are due to the treatment rather than pre-existing differences between groups. However, RCTs take many forms, and understanding their different designs, purposes, and methodological features is essential for evaluating clinical evidence. Types of Study Designs RCTs are classified by how participants move through the study. Each design has different strengths depending on the research question. Parallel-Group Design In a parallel-group design, each participant is assigned to one group—either treatment or control—and remains in that group for the entire study. This is the most common and straightforward RCT design. Participants in the treatment group receive the intervention while participants in the control group receive either a placebo, standard care, or no treatment. This design is particularly useful when you want to compare outcomes between independent groups of people. Crossover Design A crossover design differs fundamentally: each participant receives multiple interventions in a random sequence over time. For example, a participant might receive treatment A for 4 weeks, then after a "washout period," receive treatment B for 4 weeks. The participant essentially serves as their own control, which can be more efficient statistically because variation between individuals is eliminated. However, crossover designs only work when the condition is stable and treatments produce temporary effects that disappear during washout periods. They don't work well for irreversible interventions (like surgery) or conditions where the disease itself changes over time. Stepped-Wedge Design In a stepped-wedge design, clusters of participants (not individuals) gradually transition from control to intervention at randomized time points. Imagine a hospital system rolling out a new quality improvement program: perhaps 3 clinics start in January, 3 more in April, and the final 3 in July. This design is increasingly used for implementation research because it allows everyone to eventually receive the intervention while still maintaining a randomized comparison. Cluster Design A cluster design randomizes pre-existing groups (clusters) rather than individuals. Schools, villages, hospitals, or practices are randomized as whole units to either intervention or control. This is necessary when the intervention affects entire groups (like a school-wide health program) or when individual randomization would cause contamination—for example, if a teacher receives training in a new teaching method, they cannot "unlearn" it for control group students. The tradeoff is that more participants are needed because people within clusters tend to be similar to each other (correlation reduces effective sample size). Factorial Design A factorial design randomizes participants to receive every possible combination of two or more interventions. If testing drugs A and B, participants would be randomized to: A alone, B alone, both A and B, or neither. This efficiently tests multiple interventions in a single trial and can reveal interactions—whether the combination works better or worse than expected from individual effects. Trial Purpose: Explanatory vs. Pragmatic Trials are also classified by what question they answer, which drives different design choices. Explanatory Trials Explanatory trials test whether an intervention can work under ideal, tightly controlled conditions. These trials carefully select participants (often excluding those with comorbidities or other conditions), provide intensive training and supervision to those delivering the intervention, and maintain strict adherence protocols. They answer the question: "Does this intervention have an effect when used optimally?" Explanatory trials sacrifice real-world relevance for internal validity—certainty that any difference is due to the treatment. Pragmatic Trials Pragmatic trials test whether an intervention does work in routine practice with typical patients, providers, and settings. They include broader participant populations (closer to who actually uses the treatment), allow flexible delivery of the intervention, and accept lower adherence rates. They answer: "Does this intervention work in the real world where people are messy and imperfect?" Pragmatic trials sacrifice tight control for external validity—the ability to generalize findings to actual practice. The choice between explanatory and pragmatic reflects different research goals and has major implications for trial design, particularly around blinding and allocation concealment. Statistical Hypotheses: What Are Trials Designed to Show? Beyond design and purpose, trials are fundamentally classified by what statistical comparison they're testing. Superiority Trials A superiority trial aims to demonstrate that one intervention is statistically better than another. This is the standard trial: does Treatment A produce better outcomes than Treatment B or placebo? The null hypothesis is that there is no difference, and the trial succeeds if it shows a meaningful difference (usually p < 0.05). Non-Inferiority Trials A non-inferiority trial asks a different question: is a new treatment not unacceptably worse than an existing treatment? This is useful when the new treatment has other advantages (fewer side effects, lower cost, easier administration) but may not be superior in efficacy. The critical element is pre-specifying a "non-inferiority margin"—the maximum acceptable difference. For example, if a new drug for blood pressure is 15% less effective than the standard drug, is that acceptable? The margin answers that question. If the new drug is within the margin, it passes. This is trickier than superiority trials because you must show statistical similarity, not difference. Equivalence Trials An equivalence trial aims to show that two interventions produce essentially indistinguishable effects. This requires pre-specifying an equivalence margin (a range within which effects are considered equivalent) and showing that the confidence interval of the difference falls within that range. For example, comparing generic and brand-name drugs. The distinction matters: a superiority trial shows one is better, a non-inferiority trial shows one is not unacceptably worse, and an equivalence trial shows they are essentially the same. Each requires different statistical approaches. Randomization: The Process of Fair Assignment Randomization is the mechanism that ensures each participant has a known, typically equal, chance of receiving any treatment. This prevents selection bias—where sicker or more motivated people preferentially enroll in one group. Simple Randomization Simple randomization gives each participant an independent and equal probability of assignment to each group, like flipping a fair coin. It works beautifully in large trials (>200 participants) because random variation tends to balance group sizes and characteristics. However, in small trials, simple randomization can produce lopsided group sizes by chance—imagine flipping a coin 20 times and getting 15 heads. This imbalance reduces statistical power (your ability to detect a true effect). Restricted Randomization: Balancing Small Groups Restricted randomization improves balance in smaller trials by constraining randomization. Permuted-block randomization divides participants into blocks of predetermined size (commonly 4 or 6) and ensures that within each block, a fixed number are allocated to each group. If blocks of 4 are used with 1:1 allocation, each block contains exactly 2 treatment and 2 control assignments, randomized within the block. This guarantees balance at the end of each block. The risk: if someone can guess upcoming assignments (for example, if someone knows the block size and sees 3 treatment assignments in a row, they can predict the next must be control), they might selectively enroll participants. This is why allocation concealment (discussed next) is crucial to prevent this bias. Adaptive biased-coin randomization uses a different approach: the probability of assigning a participant to each group is adjusted based on the current imbalance. If treatment has far fewer enrollees, the next participant is more likely to be assigned to treatment. This mathematically optimizes balance while remaining randomized. The flow diagram above shows the typical phases of an RCT: enrollment (assessed for eligibility, excluded, then randomized), allocation (assigned to intervention or control, may not receive intended treatment), follow-up (some discontinue or drop out), and analysis (some may not be analyzed). Allocation Concealment: Hiding the Assignment Allocation concealment is distinct from randomization itself. Randomization determines which assignments are possible; allocation concealment ensures that those assignments remain hidden until the moment of assignment. Without concealment, someone enrolling participants could be tempted to selectively enroll people to one group based on predicting upcoming assignments. Common methods include: Sequentially numbered opaque sealed envelopes: Envelopes are numbered, sealed, opaque (cannot be held to light), and stored in sequence. When a participant is enrolled, the next envelope is opened, revealing their assignment. Central randomization: An independent central service (often by phone or web) receives participant information and announces the assignment, making it impossible for local staff to predict. Pharmacy-controlled dispensing: The pharmacy, blind to which treatment is which, dispenses randomized study medication, preventing researchers from knowing assignment. Poor allocation concealment is one of the most common sources of bias in trials. This is why modern standards (like CONSORT guidelines) require explicit description of how allocation was concealed. Sample Size and Power Sample size directly affects statistical power—your ability to detect a true treatment effect. Larger samples increase power; smaller samples reduce it. With insufficient sample size, a trial may fail to detect a real effect (type II error or false negative). The reverse problem also exists: trials that are too large waste resources. Sample size is determined before the trial begins using statistical formulas that consider the expected effect size, acceptable level of type I error (false positive, usually 0.05), desired power (usually 80-90%), and variability in the outcome. Blinding (Masking): Who Doesn't Know What? Blinding (also called masking) means keeping people unaware of which treatment a participant is receiving. This prevents knowledge of assignment from influencing outcome measurement or participants' responses. Types of Blinding Single-blind: Typically, participants are unaware of which treatment they receive, but researchers and care providers know. (Note: Modern standards prefer specifying exactly who is blinded rather than using vague terminology.) Double-blind: Both participants and care providers are unaware of assignment. This is the gold standard when feasible because it prevents both participant bias (placebo effects, reporting bias) and provider bias (different intensity of care, attention, or outcome ascertainment). Triple-blind: Participants, care providers, and outcome assessors are all unaware of assignment. The outcome assessor is the person measuring or evaluating the outcome (e.g., a radiologist reading X-rays, unaware of treatment group). This maximally prevents bias in outcome measurement. Modern standards from CONSORT (Consolidated Standards of Reporting Trials) recommend explicitly stating who is blinded and how (e.g., "participants and outcomes assessors were blinded; all received identical-appearing capsules"), rather than simply saying "double-blind," which is ambiguous. When Blinding Isn't Feasible Some interventions cannot be blinded to participants: Active interventions requiring participation: Physical therapy, surgery, or counseling are impossible to blind to participants because participants know whether they're doing exercises, undergoing surgery, or receiving counseling. The intervention itself is obvious. Pragmatic trials: Because pragmatic trials aim to reflect real practice, participants and providers often remain unaware of being in a trial at all, let alone blinded to group assignment. In these situations, researchers should aim to at least blind outcome assessors. For example, a physical therapy trial might be unblinded to participants and therapists, but the person measuring strength or function (the outcome assessor) can be blinded. This prevents bias in the most critical measurement. The key principle: blinding prevents bias where it's most likely to affect results. In trials where the outcome is objective (like death or hospitalization), blinding matters less. In trials where the outcome is subjective (pain, disability, mood), blinding matters more.